BR112015026095A2 - métodos para controlar a dosagem de uma droga antitumoral administrada a um paciente com câncer, para administração de pelo menos uma droga antitumoral em duas doses separadas em um paciente com câncer e para seleção de pelo menos uma droga antitumoral - Google Patents

métodos para controlar a dosagem de uma droga antitumoral administrada a um paciente com câncer, para administração de pelo menos uma droga antitumoral em duas doses separadas em um paciente com câncer e para seleção de pelo menos uma droga antitumoral

Info

Publication number
BR112015026095A2
BR112015026095A2 BR112015026095A BR112015026095A BR112015026095A2 BR 112015026095 A2 BR112015026095 A2 BR 112015026095A2 BR 112015026095 A BR112015026095 A BR 112015026095A BR 112015026095 A BR112015026095 A BR 112015026095A BR 112015026095 A2 BR112015026095 A2 BR 112015026095A2
Authority
BR
Brazil
Prior art keywords
antitumor drug
cancer
patient
cancer patient
methods
Prior art date
Application number
BR112015026095A
Other languages
English (en)
Other versions
BR112015026095A8 (pt
Inventor
Frendewey David
Thurston Gavin
D Yancopoulos George
Droguett Gustavo
Koss Matthew
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112015026095A2 publication Critical patent/BR112015026095A2/pt
Publication of BR112015026095A8 publication Critical patent/BR112015026095A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

1 / 1 resumo “mã‰todos para controlar a dosagem de uma droga antitumoral administrada a um paciente com cã‚ncer, para administraã‡ãƒo de pelo menos uma droga antitumoral em duas doses separadas em um paciente com cã‚ncer e para seleã‡ãƒo de pelo menos uma droga antitumoral” sã£o descritas composiã§ãµes e mã©todos para determinar biomolã©culas circulantes antes, durante e/ou apã³s o tratamento de um paciente com uma droga anticã¢ncer ou antitumoral (ou droga putativa). mã©todos de tratamentos com base nas composiã§ãµes e mã©todos descritos neste documento tambã©m sã£o fornecidos. mã©todos nã£o-invasivos e kits sã£o fornecidos para avaliar a eficã¡cia de uma terapia anticã¢ncer para matar ou danificar as cã©lulas cancerosas. as modalidades sã£o usadas para determinar a eficã¡cia na destruiã§ã£o do cã¢ncer de uma droga anticã¢ncer em um paciente, para otimizar a seleã§ã£o de uma droga anticã¢ncer para o tratamento de um paciente, para ajustar a dosagem de uma droga anticã¢ncer para o tratamento de um cã¢ncer especã­fico em um paciente e para identificar terapãªuticos anticã¢ncer ãºteis para qualquer tipo especã­fico de cã¢ncer.
BR112015026095A 2013-04-15 2014-04-15 método de utilizar biomarcadores responsivos ao tumor, método para seleção de pelo menos uma droga antitumoral, composição compreendendo uma droga antitumoral, combinação para controlar a dosagem de uma droga antitumoral, uso dos biomarcadores responsivos ao tumor BR112015026095A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361812033P 2013-04-15 2013-04-15
PCT/US2014/034217 WO2014172376A2 (en) 2013-04-15 2014-04-15 Markers of tumor cell response to anti-cancer therapy

Publications (2)

Publication Number Publication Date
BR112015026095A2 true BR112015026095A2 (pt) 2017-07-25
BR112015026095A8 BR112015026095A8 (pt) 2020-01-21

Family

ID=51686961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015026095A BR112015026095A8 (pt) 2013-04-15 2014-04-15 método de utilizar biomarcadores responsivos ao tumor, método para seleção de pelo menos uma droga antitumoral, composição compreendendo uma droga antitumoral, combinação para controlar a dosagem de uma droga antitumoral, uso dos biomarcadores responsivos ao tumor

Country Status (15)

Country Link
US (2) US10023916B2 (pt)
EP (1) EP2986739B1 (pt)
JP (1) JP2016518124A (pt)
KR (1) KR20150140728A (pt)
CN (1) CN105308189B (pt)
AU (1) AU2014254091B2 (pt)
BR (1) BR112015026095A8 (pt)
CA (1) CA2909642A1 (pt)
HK (1) HK1214630A1 (pt)
MX (1) MX2015014486A (pt)
MY (1) MY180365A (pt)
RU (1) RU2664180C2 (pt)
SG (2) SG10201708464TA (pt)
WO (1) WO2014172376A2 (pt)
ZA (1) ZA201507309B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9510569B2 (en) 2013-03-13 2016-12-06 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation
BR112015026095A8 (pt) 2013-04-15 2020-01-21 Regeneron Pharma método de utilizar biomarcadores responsivos ao tumor, método para seleção de pelo menos uma droga antitumoral, composição compreendendo uma droga antitumoral, combinação para controlar a dosagem de uma droga antitumoral, uso dos biomarcadores responsivos ao tumor
CN104388561A (zh) * 2014-11-14 2015-03-04 浙江理工大学 肝癌生物标记物及其用途
CN106636311B (zh) * 2015-10-30 2020-06-02 益善生物技术股份有限公司 大肠癌相关microRNA检测试剂盒
CN106636315B (zh) * 2015-10-30 2020-06-02 益善生物技术股份有限公司 淋巴瘤相关microRNA检测试剂盒
WO2017207623A1 (en) * 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
CN105950768A (zh) * 2016-07-01 2016-09-21 江苏医诺万细胞诊疗有限公司 一种microRNA组合作为肿瘤标志物辅助诊断多种肿瘤的试剂盒及其检测方法
CN106350582B (zh) * 2016-08-25 2020-02-14 朱伟 一种与肺鳞癌辅助诊断相关的血清miRNA标志物及其应用
CN106282360B (zh) * 2016-08-31 2019-11-08 武汉博杰生物医学科技有限公司 一种用于结肠癌预测转移的血浆miRNA组合、其探针组合物及应用
CN107913284B (zh) * 2016-10-09 2022-09-16 上海市东方医院 miRNA302-367簇的微小RNA在靶向抑制血管新生和肿瘤生长的应用
CN106778073B (zh) * 2017-01-19 2019-09-06 北京吉因加科技有限公司 一种评估肿瘤负荷变化的方法和系统
CN106834470A (zh) * 2017-02-17 2017-06-13 张灏 miRNA在制备癌症诊断试剂盒中的用途
CN106676196B (zh) * 2017-03-10 2019-05-07 上海核盾生物科技有限公司 一种用于诊断重度吸烟人群中肺鳞癌患者的非侵入性标记物及试剂盒
CN107326092B (zh) * 2017-08-25 2021-07-20 深圳市恩普电子技术有限公司 大肠癌相关的miRNA作为生物标志物的应用及大肠癌检测试剂盒
CN107858427B (zh) * 2017-10-24 2021-03-02 昆明理工大学 miR-429在制备乳腺癌诊断和检测试剂盒中的应用
CN108220381A (zh) * 2017-12-07 2018-06-29 国家卫生计生委科学技术研究所 试剂在制备药物中的用途以及筛选药物的方法
CN108531586B (zh) * 2018-03-19 2022-03-29 朱伟 一种与乳腺癌辅助诊断相关的位于X染色体上的循环miRNA标志物及其应用
CN109097473A (zh) * 2018-08-24 2018-12-28 南京求臻基因科技有限公司 一种非小细胞肺癌辅助诊断试剂盒
KR102256747B1 (ko) * 2018-10-30 2021-05-25 가톨릭대학교 산학협력단 엑소좀 miR-125b를 포함하는 간암 전이 진단 또는 예측용 바이오마커 및 이의 용도
CN109593852B (zh) * 2018-12-24 2022-03-08 朱伟 一种与鼻咽癌辅助诊断相关的血清miRNA标志物及其应用
US20220211822A1 (en) * 2019-05-15 2022-07-07 The University Of Chicago Lactate response system and methods
CN110484620B (zh) * 2019-08-09 2023-09-19 深圳市第二人民医院 生物标志物及其在制备诊断ptmc的产品中的应用
KR102293777B1 (ko) * 2019-12-31 2021-08-25 연세대학교 산학협력단 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법
CN113801936B (zh) * 2020-03-30 2022-04-19 中国医学科学院肿瘤医院 用于肺癌诊断的试剂盒、装置及方法
CN111808950B (zh) * 2020-06-02 2023-11-14 中南大学湘雅医院 一种甲状腺乳头状癌miRNA标志物及其应用
KR20230040989A (ko) * 2020-06-19 2023-03-23 어젠시스 인코포레이티드 항체 약물 접합체(adc)로 암을 치료하는 방법에서 사용하기 위한 마커
CN111676291B (zh) * 2020-07-14 2021-04-13 徐州医科大学 一种用于肺癌患病风险评估的miRNA标志物
CN113025713B (zh) * 2021-02-23 2022-11-22 浙江东睿生物科技有限公司 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用
CN115029347B (zh) * 2022-05-11 2024-02-20 珠海中科先进技术研究院有限公司 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒
WO2024006581A1 (en) * 2022-07-01 2024-01-04 City Of Hope Biomarkers in colorectal cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2548394A1 (en) * 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US8147827B2 (en) * 2004-06-18 2012-04-03 Genentech, Inc. Tumor treatment
EP2082741A1 (en) 2005-09-20 2009-07-29 Scinopharm Singapore Pte, Ltd. Novel crystal form of irinotecan hydrochloride
WO2008008430A2 (en) * 2006-07-13 2008-01-17 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
CA2662508A1 (en) * 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008143795A1 (en) 2007-05-11 2008-11-27 Champions Biotechnology, Inc. Human mesenchymal chrondrosarcoma xenograft model and its use in chemosensitivity testing
JP2011517283A (ja) * 2008-02-28 2011-06-02 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 前立腺関連障害の予後診断及び治療のためのマイクロｒｎａに基づく方法及び組成物
WO2009147525A1 (en) 2008-06-04 2009-12-10 Karolinska Institutet Innovations Ab Skin cancer associated micrornas
AU2009324884B2 (en) 2008-11-25 2013-10-03 Gen-Probe Incorporated Compositions and methods for detecting small RNAs, and uses thereof
WO2011040525A1 (ja) 2009-09-30 2011-04-07 財団法人ヒューマンサイエンス振興財団 大腸がん検査マーカーおよび大腸がんの検査方法
WO2011156777A1 (en) 2010-06-10 2011-12-15 Fred Hutchinson Cancer Research Center Use of blood mir-210 for cancer prognosis
WO2012128902A1 (en) 2011-03-18 2012-09-27 Baylor Research Institute Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis
JP2014526032A (ja) 2011-06-07 2014-10-02 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 癌に対する循環バイオマーカー
WO2012174293A2 (en) 2011-06-14 2012-12-20 Nestec Sa Methods for identifying inflammatory bowel disease patients with dysplasia or cancer
WO2014078850A1 (en) * 2012-11-19 2014-05-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of cancer diagnosis, progression and response to therapy using a primary xenograft mouse model for cancer serum biomarker discovery
BR112015026095A8 (pt) 2013-04-15 2020-01-21 Regeneron Pharma método de utilizar biomarcadores responsivos ao tumor, método para seleção de pelo menos uma droga antitumoral, composição compreendendo uma droga antitumoral, combinação para controlar a dosagem de uma droga antitumoral, uso dos biomarcadores responsivos ao tumor

Also Published As

Publication number Publication date
BR112015026095A8 (pt) 2020-01-21
CA2909642A1 (en) 2014-10-23
RU2015148638A (ru) 2017-05-22
MY180365A (en) 2020-11-28
AU2014254091A1 (en) 2015-11-12
EP2986739B1 (en) 2018-04-04
EP2986739A4 (en) 2017-03-01
EP2986739A2 (en) 2016-02-24
SG10201708464TA (en) 2017-11-29
US10023916B2 (en) 2018-07-17
RU2664180C2 (ru) 2018-08-15
MX2015014486A (es) 2016-07-21
SG11201508058TA (en) 2015-10-29
US20140308370A1 (en) 2014-10-16
CN105308189B (zh) 2018-09-04
WO2014172376A3 (en) 2015-10-29
AU2014254091B2 (en) 2019-03-21
JP2016518124A (ja) 2016-06-23
WO2014172376A2 (en) 2014-10-23
KR20150140728A (ko) 2015-12-16
ZA201507309B (en) 2017-08-30
US20180291468A1 (en) 2018-10-11
CN105308189A (zh) 2016-02-03
HK1214630A1 (zh) 2016-07-29

Similar Documents

Publication Publication Date Title
BR112015026095A2 (pt) métodos para controlar a dosagem de uma droga antitumoral administrada a um paciente com câncer, para administração de pelo menos uma droga antitumoral em duas doses separadas em um paciente com câncer e para seleção de pelo menos uma droga antitumoral
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
DOP2015000100A (es) Inhibidores de la tirosina-quinasa de bruton
EA201792304A1 (ru) Комбинированная терапия для лечения рака
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112015026122A8 (pt) agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
BR112016025764A2 (pt) vacina de peptídeo compreendendo peptídeo ras mutante e agente quimioterapêutico
BR112014029954A2 (pt) tratamento de tumores sólidos usando coenzima q10
MX2019003134A (es) Terapia de combinacion.
BR112018072988A2 (pt) irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula
BR112018076639A2 (pt) quimioterapias de combinação
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EA201691385A1 (ru) Комбинированная терапия рака
EA201792256A1 (ru) Соли и пролекарства 1-метил-d-триптофана
BR112018070847A2 (pt) terapias combinadas para tratamento de câncer compreendendo um derivado de bacterioclorofila
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX370519B (es) Sulfonamidas con sustitucion biarilo y su uso.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]